|
GB9326174D0
(en)
*
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
|
EP0915707B1
(en)
*
|
1996-01-25 |
2002-10-30 |
Profylakse ApS |
Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
|
|
US6818222B1
(en)
*
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
|
ATE252889T1
(de)
|
1998-08-19 |
2003-11-15 |
Skyepharma Canada Inc |
Injizierbare wässerige propofoldispersionen
|
|
US7176279B2
(en)
*
|
2000-06-28 |
2007-02-13 |
Palatin Technologies, Inc. |
Cyclic peptide compositions and methods for treatment of sexual dysfunction
|
|
US6579968B1
(en)
*
|
1999-06-29 |
2003-06-17 |
Palatin Technologies, Inc. |
Compositions and methods for treatment of sexual dysfunction
|
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
|
US7780967B2
(en)
*
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
|
US8632785B2
(en)
*
|
2000-02-08 |
2014-01-21 |
Allergan, Inc. |
Clostridial toxin pharmaceutical composition containing a gelatin fragment
|
|
US20060269575A1
(en)
*
|
2000-02-08 |
2006-11-30 |
Allergan, Inc. |
Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
|
|
CA2494241C
(en)
*
|
2000-02-08 |
2011-06-14 |
Allergan, Inc. |
Botulinum toxin pharmaceutical compositions
|
|
US6623765B1
(en)
|
2000-08-01 |
2003-09-23 |
University Of Florida, Research Foundation, Incorporated |
Microemulsion and micelle systems for solubilizing drugs
|
|
AU2002238106A1
(en)
*
|
2001-02-13 |
2002-08-28 |
Palatin Technologies, Inc. |
Melanocortin metallopeptides for treatment of sexual dysfunction
|
|
US7342089B2
(en)
*
|
2001-07-11 |
2008-03-11 |
Palatin Technologies, Inc. |
Cyclic peptides for treatment for cachexia
|
|
US7345144B2
(en)
*
|
2001-07-11 |
2008-03-18 |
Palatin Technologies, Inc. |
Cyclic peptides for treatment of cachexia
|
|
WO2003072016A2
(en)
*
|
2001-11-19 |
2003-09-04 |
Becton, Dickinson And Company |
Pharmaceutical compositions in particulate form
|
|
WO2004005324A2
(en)
*
|
2002-07-09 |
2004-01-15 |
Palatin Technologies, Inc. |
Peptide composition for treatment of sexual dysfunction
|
|
CA2531491A1
(en)
*
|
2003-07-15 |
2005-02-03 |
University Of Maryland, Baltimore |
Agonist polypeptide of receptor for zot and zonulin
|
|
US20060263350A1
(en)
*
|
2003-09-26 |
2006-11-23 |
Fairfield Clinical Trials Llc |
Combination antihistamine medication
|
|
DE10351778A1
(de)
|
2003-11-06 |
2005-06-09 |
Daimlerchrysler Ag |
Verfahren zur Korrespondenzanalyse in Bilddatensätzen
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
US20060210614A1
(en)
*
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20080318837A1
(en)
*
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
|
US20060074025A1
(en)
*
|
2003-12-26 |
2006-04-06 |
Nastech Pharmaceutical Company Inc. |
Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
|
|
US6974187B2
(en)
*
|
2004-01-28 |
2005-12-13 |
Tachi-S Co., Ltd. |
Vehicle seat structure
|
|
WO2006088491A2
(en)
*
|
2004-06-29 |
2006-08-24 |
Massachusetts Institute Of Technology |
Methods and compositions related to the modulation of intercellular junctions
|
|
TW200637573A
(en)
*
|
2005-01-14 |
2006-11-01 |
Univ Maryland |
Peptide for delivery of mucosal vaccines
|
|
TW200716159A
(en)
*
|
2005-06-09 |
2007-05-01 |
Univ Maryland |
Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
|
|
US7754691B1
(en)
|
2005-07-07 |
2010-07-13 |
Palatin Technologies, Inc. |
Linear melanocortin receptor-specific peptides for cachexia
|
|
US8247530B2
(en)
*
|
2005-11-08 |
2012-08-21 |
Palatin Technologies, Inc. |
N-alkylated cyclic peptide melanocortin agonists
|
|
EP1959987A2
(en)
*
|
2005-12-08 |
2008-08-27 |
Nastech Pharmaceutical Company Inc. |
Mucosal delivery of stabilized formulations of exendin
|
|
US20070232537A1
(en)
*
|
2005-12-19 |
2007-10-04 |
Nastech Pharmaceutical Company Inc. |
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
|
BRPI0707616A2
(pt)
|
2006-02-09 |
2011-05-10 |
Alba Therapuetics Corp |
formulaÇÕes para um efetor de junÇço oclusiva
|
|
US7795221B2
(en)
*
|
2006-03-30 |
2010-09-14 |
Palatin Technologies, Inc. |
Linear natriuretic peptide constructs
|
|
EP2001518B1
(en)
|
2006-03-30 |
2013-07-10 |
Palatin Technologies, Inc. |
Cyclic natriuretic peptide constructs
|
|
US8580746B2
(en)
*
|
2006-03-30 |
2013-11-12 |
Palatin Technologies, Inc. |
Amide linkage cyclic natriuretic peptide constructs
|
|
US8728491B2
(en)
*
|
2007-05-07 |
2014-05-20 |
Alba Therapeutics Corporation |
Transcutaneous delivery of therapeutic agents
|
|
WO2009015382A2
(en)
|
2007-07-26 |
2009-01-29 |
Alba Therapeutics Corporation |
Novel peptides that enhance tight junction permeability
|
|
WO2010065802A2
(en)
|
2008-12-04 |
2010-06-10 |
Palatin Technologies, Inc. |
Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
|
|
WO2010065801A1
(en)
|
2008-12-04 |
2010-06-10 |
Palatin Technologies, Inc. |
Amine substituted piperazine melanocortin receptor-specific compounds
|
|
WO2010065799A2
(en)
|
2008-12-04 |
2010-06-10 |
Palatin Technologies, Inc. |
Amine substituted piperidine melanocortin receptor-specific compounds
|
|
US9717867B2
(en)
|
2009-02-27 |
2017-08-01 |
Pari GmbH Spezialisten für effektive Inhalation |
Method for operating an aerosol inhalation device and aerosol inhalation device
|
|
CA2761607C
(en)
|
2009-06-08 |
2018-09-04 |
Yi-Qun Shi |
Melanocortin receptor-specific peptides
|
|
EP2380618A1
(en)
*
|
2010-04-26 |
2011-10-26 |
PARI Pharma GmbH |
Operating method for an aerosol delivery device and aerosol delivery device
|
|
EP2814501A4
(en)
|
2012-03-13 |
2016-03-02 |
Tensive Controls Inc |
MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
|
|
CA2875384A1
(en)
|
2013-12-20 |
2015-06-20 |
AntiOP, Inc. |
Intranasal naloxone compositions and methods of making and using same
|
|
US10085937B2
(en)
|
2014-03-14 |
2018-10-02 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
RU2016136714A
(ru)
|
2014-03-14 |
2018-04-19 |
ОПИАНТ ФАРМАСЮТИКАЛС, Инк. |
Назальные готовые лекарственные формы и способы их применения
|
|
US9480644B2
(en)
|
2014-03-14 |
2016-11-01 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
US9561177B2
(en)
|
2014-03-14 |
2017-02-07 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
WO2016044683A1
(en)
|
2014-09-19 |
2016-03-24 |
Tensive Controls, Inc. |
Anti-microbial peptides
|
|
US11590209B2
(en)
|
2020-01-21 |
2023-02-28 |
Palatin Technologies, Inc. |
Use of bremelanotide in patients with controlled hypertension
|